Literature DB >> 14870947

The Barnes Akathisia Rating Scale--revisited.

Thomas R E Barnes1.   

Abstract

Akathisia is a syndrome of motor restlessness, principally seen in association with antipsychotic medication. It is characterized by a subjective experience of mental unease and the urge to move, and manifests physically as particular patterns of restless movement. This review focuses on the signs and symptoms of the condition, and its diagnosis and assessment using the Barnes Akathisia Rating Scale. This scale was generated 15 years ago, and was derived from the findings of studies exploring the clinical features of antipsychotic-induced akathisia. Subsequently, its validity and reliability have been established, and it has been used extensively in clinical studies worldwide.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14870947     DOI: 10.1177/0269881103174013

Source DB:  PubMed          Journal:  J Psychopharmacol        ISSN: 0269-8811            Impact factor:   4.153


  37 in total

1.  Cognitive-behavioral therapy vs risperidone for augmenting serotonin reuptake inhibitors in obsessive-compulsive disorder: a randomized clinical trial.

Authors:  Helen Blair Simpson; Edna B Foa; Michael R Liebowitz; Jonathan D Huppert; Shawn Cahill; Michael J Maher; Carmen P McLean; James Bender; Sue M Marcus; Monnica T Williams; Jamie Weaver; Donna Vermes; Page E Van Meter; Carolyn I Rodriguez; Mark Powers; Anthony Pinto; Patricia Imms; Chang-Gyu Hahn; Raphael Campeas
Journal:  JAMA Psychiatry       Date:  2013-11       Impact factor: 21.596

2.  Asenapine in the management of impulsivity and aggressiveness in bipolar disorder and comorbid borderline personality disorder: an open-label uncontrolled study.

Authors:  Andrea Aguglia; Ludovico Mineo; Alessandro Rodolico; Maria S Signorelli; Eugenio Aguglia
Journal:  Int Clin Psychopharmacol       Date:  2018-05       Impact factor: 1.659

3.  Psychometric properties of the Treatment-Emergent Activation and Suicidality Assessment Profile (TEASAP) in youth with OCD.

Authors:  Regina Bussing; Tanya K Murphy; Eric A Storch; Joseph P H McNamara; Adam M Reid; Cynthia W Garvan; Wayne K Goodman
Journal:  Psychiatry Res       Date:  2012-09-29       Impact factor: 3.222

4.  Patterns of co-altered brain structure and function underlying neurological soft signs in schizophrenia spectrum disorders.

Authors:  Dusan Hirjak; Mahmoud Rashidi; Stefan Fritze; Alina L Bertolino; Lena S Geiger; Zhenxiang Zang; Katharina M Kubera; Mike M Schmitgen; Fabio Sambataro; Vince D Calhoun; Matthias Weisbrod; Heike Tost; Robert C Wolf
Journal:  Hum Brain Mapp       Date:  2019-08-12       Impact factor: 5.038

5.  Adjunctive varenicline treatment with antipsychotic medications for cognitive impairments in people with schizophrenia: a randomized double-blind placebo-controlled trial.

Authors:  Joo-Cheol Shim; Do-Un Jung; Sung-Soo Jung; Young-Soo Seo; Deuk-Man Cho; Ji-Heon Lee; Sae-Woom Lee; Bo-Geum Kong; Je-Wook Kang; Min-Kyung Oh; Sang-Duk Kim; Robert P McMahon; Deanna L Kelly
Journal:  Neuropsychopharmacology       Date:  2011-11-02       Impact factor: 7.853

6.  Six-month outcomes from a randomized trial augmenting serotonin reuptake inhibitors with exposure and response prevention or risperidone in adults with obsessive-compulsive disorder.

Authors:  Edna B Foa; Helen Blair Simpson; David Rosenfield; Michael R Liebowitz; Shawn P Cahill; Jonathan D Huppert; James Bender; Carmen P McLean; Michael J Maher; Raphael Campeas; Chang-Gyu Hahn; Patricia Imms; Anthony Pinto; Mark B Powers; Carolyn I Rodriguez; Page E Van Meter; Donna Vermes; Monnica T Williams
Journal:  J Clin Psychiatry       Date:  2015-04       Impact factor: 4.384

7.  Heterogeneity of Treatment Effects of Long-Acting Injectable Antipsychotic Medications.

Authors:  T Scott Stroup; Natalie A Bareis; Robert A Rosenheck; Marvin S Swartz; Joseph P McEvoy
Journal:  J Clin Psychiatry       Date:  2018-11-27       Impact factor: 4.384

8.  An open-label, rater-blinded, augmentation study of aripiprazole in treatment-resistant depression.

Authors:  Ashwin A Patkar; Kathleen Peindl; Rajnish Mago; Paolo Mannelli; Prakash S Masand
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2006

9.  Working memory and DLPFC inefficiency in schizophrenia: the FBIRN study.

Authors:  S G Potkin; J A Turner; G G Brown; G McCarthy; D N Greve; G H Glover; D S Manoach; A Belger; M Diaz; C G Wible; J M Ford; D H Mathalon; R Gollub; J Lauriello; D O'Leary; T G M van Erp; A W Toga; A Preda; K O Lim
Journal:  Schizophr Bull       Date:  2008-11-27       Impact factor: 9.306

Review 10.  Upcoming agents for the treatment of schizophrenia: mechanism of action, efficacy and tolerability.

Authors:  Delia Bishara; David Taylor
Journal:  Drugs       Date:  2008       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.